Pfizer (PFE) said it was granted HSR early termination by the Federal Trade Commission for its planned purchase of Metsera (MTSR).
The termination of the waiting period satisfies the regulatory review requirements, which was set to expire on Nov. 7, Pfizer said in a statement on Friday.
The regulatory approval comes a day after Novo Nordisk (NVO) outbid Pfizer (PFE) for Metsera (MTSR). Pfizer has until Tuesday to match the offer, which Metsera (MTSR) deemed as “superior.”
Pfizer (PFE) on Thursday called the Metsera (MTSR) bid ” an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk.
